Claritev Corporation

The current price of CTEV is $22.71 — it has increased by 12.31% since the previous close. Data as of Nov 6, 2026.

CTEV is down 7.04% over the past week, down 9.27% over the past month and down 67.21% over the past year. The price is below its 200-day moving average of $25.47.

Analysts' average 12-month price target for CTEV is $52.00, which implies 128.97% upside from the current price. Individual estimates range from $40.00 to $73.00.

Of the 5 analysts covering Claritev Corporation, 2 rate it a strong buy, 2 rate it a buy and 1 rates it a hold. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.

Claritev Corporation has a market capitalization of $384.88M. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.

In its most recent quarterly report, Claritev Corporation posted a loss of $3.49 per share against an estimate of -$4.12, beating expectations by 15.29%. Upcoming reports are listed in the earnings calendar.

Claritev Corporation reported revenue of $257.48M in its most recent quarter, which has increased by 6.59% compared with the same quarter a year earlier. Analysts had expected $244.81M.

Claritev Corporation has not paid any dividends over the past year.

Companies most comparable to Claritev Corporation include Dianthus Therapeutics, Inc., AxoGen, Inc., OPKO Health, Inc., GoodRx Holdings, Inc. and Integra LifeSciences Holdings Corporation.

In the latest trading session CTEV moved between $19.95 and $23.51, a range of 15.68% of its current price.

Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of Claritev Corporation shows a sell rating today and a sell rating on the weekly timeframe. Technical ratings are indicators, not investment advice.

Over the past 52 weeks CTEV has traded between $11.50 and $72.67. The current price is 68.75% below its 52-week high.